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Background Telephone therapist delivered CBT (TCBT) and web-based CBT (WCBT) have been shown 
to be significantly more clinically effective than treatment as usual (TAU) at reducing IBS symptom 
severity and impact at 12 months in adults with refractory IBS. In this paper we assess the cost-
effectiveness of the interventions.  
Methods Participants were recruited from 74 general practices and three gastroenterology centres 
in England. Interventions costs were calculated, and other service use and lost employment 
measured and costed for one-year post randomisation. Quality-adjusted life years (QALYs) were 
combined with costs to determine cost-effectiveness of TCBT and WCBT compared to TAU. 
Results TCBT cost £956 more than TAU (95% CI, £601 to £1435) and generated 0.0429 more QALYs. 
WCBT cost £224 more than TAU (95% CI, -£11 to £448) and produced 0.029 more QALYs. Compared 
to TAU, TCBT had an incremental cost per QALY of £22,284 while the figure for WCBT was £7724. 
After multiple imputation these ratios increased to £27,436 and £17,388 respectively. Including lost 
employment and informal care, TCBT had costs that were on average £866 lower than TAU (95% CI, -
£1133 to £2957), and WCBT had costs that were £1028 lower than TAU (95% CI, -£448 to £2580). 
Conclusions TCBT and WCBT resulted in more QALYs and higher costs than TAU. Complete case 
analysis suggests both therapies are cost-effective from a healthcare perspective. Imputation for 
missing data reduces cost-effectiveness but WCTB remained cost-effective. If the reduced societal 
costs are included both interventions are likely to be more cost-effective. 
Trial registration ISRCTN44427879 (registered 18.11.13) 
 







Irritable bowel syndrome (IBS) is a common condition with a prevalence of 10-20%.1 Because of 
clinical symptoms including abdominal pain, altered bowel habit, and bloating, IBS has a negative 
impact on quality of life of those experiencing it.2 Treatment options for IBS are varied, and include 
pharmacological interventions, life style changes, and psychological therapies.3 Given the limited 
availability of healthcare resources it is imperative to assess the relative cost-effectiveness of 
alternative ways of providing care. 
 
Economic evaluations of treatments for IBS have been conducted previously. A study from Sweden 
compared internet therapy with usual care.4 At 12-month follow-up the intervention group had 
lower severity of symptoms and lower societal costs, and a 79% likelihood of being a dominant 
option. Previously, McCrone et al found that nurse-delivered CBT in addition to mebeverine had 
reasonable likelihood of cost-effectiveness after three months but not beyond this.5 Elsewhere, 
acupuncture has been evaluated in a trial as a treatment for IBS compared to usual care.6 Quality-
adjusted life years (QALYs) were higher for the acupuncture group but costs were higher, resulting in 
an incremental cost-effectiveness ratio of £62,500 which exceeds the threshold of £20,000 to 
£30,000 used in England by the National Institute for Health and Care Excellence (NICE). 
 
We recently conducted a three-arm randomised controlled trial (n= 558) comparing telephone-
delivered cognitive behavioural therapy (TCBT), web-delivered cognitive behavioural therapy (WCBT) 
and treatment as usual (TAU).7,8 Both TCBT and WCBT were superior to TAU in terms of 
improvements in the primary outcomes, IBS symptom severity and impact of IBS on life roles (daily 
functioning) up to 12 months follow-up. They were also superior on a range of secondary outcomes 
(global symptom relief, anxiety, depression, and cognition). The aims of this paper are to (i) 
investigate the differences in health service and societal costs between participants allocated to 
TCBT, WCBT or TAU and (ii) compare cost-effectiveness of TCBT and WCBT compared to TAU in 
terms of quality-adjusted life years (QALYs) over the 12-month follow-up. 
 
Methods 
Setting and sample 
The study recruited from primary care (74 general practices) and secondary care (three 
gastroenterology centres) settings in the UK between May 2014 and March 2016. The sample 
consisted of adults with refractory IBS (clinically significant symptoms for 12 months despite being 
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offered first line therapies). Full details of the inclusion and exclusion criteria and flow through the 
trial are provided in the published protocol and clinical results.7,8 
 
Interventions 
Participants were randomised with an independent web-based service at the level of the individual 
with varying block sizes to receive TCBT plus TAU, WCBT plus TAU or TAU alone. TCBT consisted of a 
patient CBT self-management manual,9 six 60-minute telephone sessions over nine weeks, and two 
60-minute booster sessions at four and eight months (eight hours of therapist time). Although 
therapist training and supervision was provided, we have assumed that the cost of this are 
contained within the unit cost used for therapist time. WCBT consisted of interactive, tailored web-
based CBT (WCBT), three 30-minute telephone sessions over nine weeks, and two 30-minute 
boosters at four and eight months (two and a half hours of therapist time). TAU consisted of usual 
healthcare consultations and medication. Those delivering therapy could not be blinded to 
treatment. The economic analyses required knowledge if which therapy was provided and so 
economists were also not blinded.  
 
Outcomes 
Baseline assessments were conducted with follow-ups at three, six, and 12 months following 
randomisation. The two co-primary outcome measures were the IBS Symptom Severity Score (IBS 
SSS) and the Work and Social Adjustment Scale (WSAS). The IBS SSS is a 500 point scale with higher 
scores indicating greater symptomatology,10 while the WSAS is a 40 point scale with higher scores 
indicating lower levels of daily functioning.11 The main outcome measure used in the health 
economic analyses was the EQ-5D-5L.12 This instrument scores five domains (mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression) as 1 (representing no problems), through 
to 5 (extreme problems). The resulting five-digit score represents a unique health state and this is 
converted to a value anchored by 1 (full health) and 0 (death). Area under the curve methods are 
then used to combine these weights at baseline and each follow-up to generate QALYs. This method 
assumed a linear change between quality of life scores.13 
 
Service use and costs 
Costs were measured from both a health service and a societal perspective (the latter including 
family care costs and lost employment costs). TCBT and WCBT costs were based on the number of 
telephone sessions with therapists and the unit cost of therapist time. This was calculated using a 
therapy cost of £98 per session reported in the Personal Social Services Research Unit’s annual 
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compendium,14 adjusted for the time spent using therapy. The median length of TCBT sessions was 
55 minutes and combined with the £98 this produced a cost per minute of therapist time which was 
combined with TCBT and WCBT therapy time. The development and maintenance costs (including 
the fee for hosting the site) of WCBT were estimated and apportioned appropriately. This was 
apportioned over trial participants and was estimated at £13.51 per participant in the trial. (Clearly if 
the intervention were rolled out to a wider population then the development costs per person 
would become very small.) Use of other services was measured with the self-report Client Service 
Receipt Inventory (CSRI) at baseline (for the previous six months) and each follow-up (covering the 
period since the previous interview).15 Services included in the CSRI primary and secondary 
healthcare contacts, inpatient stays, investigations, and medication. Costs were generated by 
combining this information with appropriate unit cost information for 2015/16.14,16,17 These service 
costs were added to the intervention costs. The unit costs used are available in the Appendix. 
 
Costs to society were estimated by including informal care costs and those resulting from time off 
work. Informal care costs were calculated by asking participants to say how much time per week 
family members and friends typically spent providing help in specific areas due to problems 
associated with IBS. This time was combined with an average hourly wage rate of £15.73 to 
represent the opportunity cost of informal care.18 The number of days lost from work was recorded 
and combined with an average daily wage rate of £105 to generate lost production costs. We did not 
include patient time costs incurred while using the interventions. 
 
Analyses 
Comparisons of costs were made at three, six and 12 months as well as the entire follow-up period, 
with baseline costs controlled for. (This is common practice in health economic studies given the 
usual wide variation in costs. Such variation can often be associated with baseline costs.) The costs 
of the interventions were only added to the costs for the whole follow-up period. The cost 
comparisons used regression models with baseline costs entered as an independent variable along 
with site variables as stratifiers and with bootstrapped percentile 95% confidence intervals 
generated around the coefficients. Medication costs were calculated but excluded from the analyses 
due to substantial missing data. 
 
Cost-effectiveness analyses were conducted from a healthcare perspective on cases where data on 
both costs and QALYs were available. Incremental cost-effectiveness ratios were produced, and 
uncertainty addressed using cost-effectiveness planes (CEPs) and cost-effectiveness acceptability 
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curves (CEACs). The CEPs and CEACs were produced from incremental costs and QALYs generated 
from bootstrapped resamples of the original data. The range of threshold values used in the CEAC 
was £0 to £60,000 (so including the £20,000-£30,000, which guides decisions made by the National 
Institute for Health and Care Excellence in England). 
 
We conducted sensitivity analyses by changing the intervention costs upwards and downwards by 
25% and 50%. This was done because in other settings therapy might be delivered by professionals 
at a higher or lower pay grade. Sensitivity analyses were also conducted by using the minimum wage 
of £7.50 per hour to calculate informal care and lost days from work (assuming 7.5 hours per day) 
and by using the unit cost of a home care worker (£20 per hour) to value informal care. 
Furthermore, missing cost and EQ-5D-5L data were imputed using multiple imputation methods on 
1000 bootstrapped resamples. We assumed that data were missing at random and that potential 
predictors of costs and EQ-5D-5L scores (at each follow-up point) were corresponding costs and EQ-
5D-5L scores from other time points and also the primary clinical measures (IBS-SSS and WSAS). The 
imputation was conducted on each bootstrapped resample in turn and used chained equations and 
predictive mean matching based on the five nearest neighbours. The mean of the cost and QALY 
differences from the 1000 resamples was extracted and reported. 
 
Patient and public involvement (PPI) representatives participated in the trial management group and 
trial steering committee and were included in all phases of trial design, including planning 





The sample at baseline numbered 558 and is described in detail elsewhere with a consort diagram of 
patient flow for clinical outcomes.8 Baseline clinical and demographic characteristics are shown in 
Table 1 and these indicate that at baseline the groups were well balanced. Around three-quarters of 
the participants were female and nearly all of white ethnicity. Only about one-tenth had seen a 
specialist for IBS symptoms even though the duration of symptoms was on average over six years. 







Service use and lost employment data were available for 186 TCBT, 185 WCBT and 187 TAU 
participants at baseline. At three-month follow-up the figures were 142 (76% of baseline number) 
for TCBT, 132 (71%) WCBT and 134 (72%) TAU; six-month follow-up 135 (73%) TCBT, 115 (62%) 
WCBT and 128 (68%) TAU; 12-month follow-up 130 (70%) TCBT, 120 (65%) WCBT and 130 (70%) 
TAU. During the six-month period prior to baseline assessment, over four-fifths of participants had 
contacts with a GP (Table 2). The use of other doctors, practice nurses and pharmacists were 
relatively high compared to use of other services. Few participants had inpatient stays. More than 
half of each group used medication related to IBS. For about three-quarters of the sample, 
investigations (usually blood tests) were performed. Around one-fifth of each group received care 
from family or friends because of health problems. In the period up to three-month follow-up, about 
half the participants in each group had GP contacts. Pharmacists contacts was the next most used 
service. There were only slight differences between groups in terms of use of services. In the next 
period, up to the six-month follow-up, there were similar levels of service use as observed 
previously. Around half the participants received GP care and around one-quarter had contacts with 
pharmacists. In the final six-month period, up to 12-month follow-up, the most commonly used 
services were GPs, other doctors, pharmacists, and practice nurses. Use of inpatient care was slightly 
higher than previously. 
 
Table 3 shows the mean number of service contacts for those participants who had at least one 
contact. For most services the number of is less than ten and there are few notable differences 
between the groups. However, for those who received informal care, the TAU group had more hours 
a week than the other two groups during the follow-up periods.  
 
Costs 
At baseline, inpatient care, although used by few participants, had the highest costs, along with GP 
and contacts with other doctors (Table 4). The groups did not differ much in terms of costs of 
particular services. Total healthcare costs were on average £681 for TCBT, £620 for WCBT, and £802 
for TAU. TAU participants had costs that were £122 more than for TCBT and £182 more than for 
WCBT. With informal care and lost employment costs included, the total was £1995 for TCBT, £1965 
for WCBT, and £2352 for TAU. TCBT had total costs that were £357 less than for TAU and WCBT had 




In the period up to three-month follow-up the costs again were relatively high for GP and other 
doctor contacts. Inpatient costs for the WCBT group were higher than for the other groups. The 
average healthcare costs excluding the intervention were £271 for TCBT, £346 for WCBT, and £227 
for TAU. Adjusting for baseline, the TCBT group had healthcare costs that were £54 higher than for 
TAU (bootstrapped 95% CI, −£61 to £174) and WCBT had costs that were £151 higher than for TAU 
(bootstrapped 95% CI, −£71 to £510). Mean societal costs (including informal care and lost 
employment) were £682 for TCBT, £723 for WCBT, and £836 for TAU. Adjusting for baseline, TCBT 
had mean total costs that were £25 higher than for TAU (bootstrapped 95% CI, −£321 to £386) and 
WCBT had mean total costs that were £218 higher than for TAU (bootstrapped 95% CI, −£236 to 
£665). 
 
In the three months up to the six-month follow-up, costs were highest for GPs and other doctors. 
Average non-intervention healthcare costs were £281 for TCBT, £224 for WCBT, and £206 for TAU. 
After adjusting for baseline costs TCBT had £86 higher costs than TAU (bootstrapped 95% CI, −£33 to 
£234) and WCBT had costs that were £39 higher than for TAU (bootstrapped 95% CI, −£68 to £155. 
Informal care costs were very different between groups during this period. Average societal costs 
were £840 for TCBT, £503 for WCBT, and £1344 for TAU. Adjusting for baseline resulted in TCBT 
having costs that were on average £343 less than for TAU (bootstrapped 95% CI, −£266 to £1022) 
and WCBT having costs that were £420 lower than for TAU (bootstrapped 95% CI, −£57 to £1009).  
 
In the six months up to the 12-month follow-up, average healthcare costs (excluding the 
intervention) were £519 for TCBT, £325 for WCBT, and £393 for TAU. After adjusting for baseline, 
TCBT had non-intervention healthcare costs that were on average £144 more than for TAU 
(bootstrapped 95% CI, −£119 to £499) and WCBT had costs that were £42 lower than for TAU 
(bootstrapped 95% CI, −£124 to £210). The higher level of informal care costs for TAU continued 
during this period. The TAU group also had higher lost employment costs than the other groups. 
Mean societal costs (including informal care and lost employment) were £1055 for TCBT, £1029 for 
WCBT, and £2103 for TAU. After adjusting for baseline, TCBT had costs that were £873 lower than 
for TAU (bootstrapped 95% CI, −£223 to £2153) and WCBT had costs that were £751 lower than for 
TAU (bootstrapped 95% CI, −£180 to £1885). 
 
Mean (SD) total healthcare costs, with ACTIB CBT costs included, over the whole one-year follow-up 
period were £1650 (£1931) for TCBT, £943 (£955) for WCBT, and £715 (£884) for TAU. Adjusting for 
baseline, TCBT had costs that were on average £943 higher than for TAU which was statistically 
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significant (bootstrapped 95% CI, £572 to £1363) and WCBT had costs that were £278 higher than 
for TAU which was also significant (bootstrapped 95% CI, £11 to £514). Cost differences for 
participants where EQ-5D-5L data were available (which is relevant for the complete case analysis) 
were £956 (bootstrapped 95% CI, £601 to £1435) for TCBT and £224 for WCBT (bootstrapped 95% 
CI, -£11 to £448).  
The mean (SD) societal costs over the one-year follow-up period, again including ACTIB CBT  costs, 
were £3065 (£5179) for TCBT, £2094 (£3069) for WCBT, and £4374 (£11,843) for TAU. After 
adjusting for baseline, TCBT had costs that were £866 lower than TAU (bootstrapped 95% CI, −£1133 
to £2957) and WCBT had costs that were £1028 lower than for TAU (bootstrapped 95% CI, −£448 to 
£2580).  
 
Quality-adjusted life years 
Response to the EQ-5D-5L was relatively low (Table 5). Utility scores were high for each group at 
each time point. Improvements were greater for the TCBT and WCBT groups compared to TAU. After 
adjustment for baseline EQ-5D-5L utility scores, it was shown that TCBT resulted in 0.0414 more 
QALYs than TAU (95% CI, 0.0194 to 0.0635) and WCBT resulted in 0.0269 more QALYs than TAU (95% 
CI, 0.0041 to 0.0497). Differences in QALYs for those with follow-up cost data were 0.0429 (95% CI, 
0.0205 to 0.0653 and 0.0290 (95% CI, 0.0063 to 0.0518) respectively. Table 5 also reveals that there 
was a substantial amount of missing EQ-5D-5L data. Reasons for this are addressed in the Discussion.  
 
Cost-effectiveness results – complete case analyses 
Data were available on healthcare costs and QALYs for 99 (53%) TCBT participants, 92 (50%) WBT 
participants, and 100 (53%) TAU participants. Dividing incremental healthcare costs by incremental 
QALYs differences for those with both cost and QALY data results in the following incremental cost-
effectiveness ratios (ICERs): TCBT v TAU £22,284 and WCBT v TAU £7724. The ICER for TCBT 
compared to WCBT was £52,662.  
 
Uncertainty around the ICERs is illustrated in Figures 1-3. Each point on the cost-effectiveness planes 
represent a pair of incremental costs and QALYs from 1000 bootstrapped samples. From Figure 1 we 
see that TCBT compared to TAU is certain to result in higher healthcare costs and to produce more 
QALYs. Comparing WCBT to TAU (Figure 2), there is a 96.2% likelihood that WCBT has higher 
healthcare costs than TAU and produces more QALYs, a 3.2% likelihood of lower costs and more 
QALYs, a 0% likelihood of lower costs and fewer QALYs, and a 0.6% likelihood of higher costs and 
fewer QALYs. The cost-effectiveness acceptability curves show that at very low values placed on a 
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QALY gain, TAU is likely to be the most cost-effective option (Figure 3). When higher values are 
placed on a QALY, WCBT becomes the most likely to be cost-effective. The likelihood that TCBT is the 
most cost-effective option does increase but only exceeds the probability of WCBT at around 
£55,000 per QALY. At a £20,000 threshold (commonly used in evaluations in England), WCBT is most 




After multiple imputation for missing EQ-5D-5L-based utility scores and costs it was found that TCBT 
had an ICER of £27,436 per QALY compared to TAU. WCBT resulted in an ICER of £17,388 per QALY. 
When therapy costs were reduced by 25% and 50% the ICERs from the healthcare perspective 
compared to TAU were reduced for both groups and the ICER for TCBT was now well below the 
£20,000 threshold (Table 6). When therapy costs were increased the WCBT option was still well 
below the £20,000 threshold. 
 
When the minimum wage was used to value informal care and lost work days, mean societal costs 
reduced to £2362 for TCBT, £1520 for WCBT and £2518 for TAU. After adjusting for baseline, TCBT 
had costs that were £45 higher than for TAU (bootstrapped 95% CI, -£1145 to £1124) and WCBT had 
costs that were £389 lower than for TAU (bootstrapped 95% CI, £391 to £1283). When the cost of a 
homecare worker was used to value informal care, the mean societal costs were £3281 for TCBT, 
£2275 for WCBT and £5098 for TAU. After adjusting for baseline, TCBT had costs that were £1228 
lower than for TAU (bootstrapped 95% CI, £1061 to £3917) and WCBT had costs that were £1241 
lower than for TAU (bootstrapped 95% CI, £498 to £3351). 
 
Discussion 
These cost-effectiveness analyses found that TCBT and WCBT resulted in increased healthcare costs 
over the follow-up period. Higher costs can be justified if outcomes are improved sufficiently. The 
complete case analysis revealed that the cost per QALY for WCBT was lower than the threshold 
often assumed to guide NICE decisions in England (£20,000). TCBT on the other hand had a cost-
effectiveness ratio slightly above this threshold. On this basis, WCBT would be the preferred option.  
 
However, there was much missing EQ-5D-5L data. This was due to the requirement placed on the 
trial to use the EuroQol online website to collect the EQ-5D data which required electronic transfer 
of participants from the trial data collection software platform to the EQ-5D website to input the 
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data. This did not always work effectively, and so data collection was not always completed. With 
imputation for the missing data, the ICERs both increased substantially. TCBT would be now more 
unlikely to be considered cost-effective at such a ratio (the ICER being over £30,000) but WCBT 
would still be below the NICE threshold.  
 
A strength of the study was the comprehensive approach to costing adopted. Both TCBT and WCBT 
resulted in lower societal costs than TAU. This was because of reduced informal care from family and 
friends compared to TAU. There was though no evidence that lost work time differed between the 
groups. From this societal perspective we may deduce that TCBT and WCBT both dominate TAU (i.e. 
they are more effective and less expensive). However, the confidence intervals are wide and do not 
exclude zero cost differences. NICE do not usually consider carer costs in their decision-making 
process though it could be argued with increasing integration of health and social care services and 
budgets that these are becoming more important to consider. This is a key strength of the study as 
interventions such as these seem to have benefits outside of the healthcare system. From an 
economic perspective all relevant effects should be included and costs computed.  
 
Elsewhere, Andersson et al found that internet-based therapy resulted in reduced societal costs for 
patients compared to participating in a discussion group.19 This coupled with improved outcomes 
resulted in internet therapy being highly cost-effective. In a subsequent study, Ljótsson et al found 
similar results when comparing internet therapy to a waiting list condition. In our study we have 
focussed on healthcare costs given that these are the main consideration for NICE in England.4 
 
Limitations 
There were limitations to this economic evaluation. First, and most importantly, the quantity of 
missing EQ-5D-5L data was a concern. Those with missing data had worse IBS-SSS and WASAS scores 
at each time point and so imputation from these resulted in smaller QALY gains for TCBT and WCBT 
relative to TAU (details available from authors).  
 
Second, service use data were provided by participants themselves and there may have been recall 
accuracy problems. However, this would not likely affect one group more than another and it was 
the only option for collecting comprehensive data. Third, medication data were not of high quality. 
We did know what medications were taken but quantities and durations were not complete. Many 
medications were bought ‘over the counter’ and exact details may not have always been available. 
However, these costs would be a small proportion of the total healthcare cost and their inclusion 
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would have only a marginal effect. We might though have expected TAU to result in higher 
medication costs in the absence of an active therapy.  
 
Third, the economic analyses were trial based and so limited to the 12-month follow-up period. It 
could well be that economic impacts continue beyond this time and modelling to extrapolate these 
results is warranted. 
 
Finally, the intervention costs for WCBT were apportioned over the trial population. If both forms of 
ACTIB CBT were rolled out over a larger patient population then the fixed costs of the intervention 
would fall per patient.  
 
We believe this to be the largest trial of CBT for IBS worldwide to date and the first to evaluate 
telephone and web-based CBT in the same trial. It was a rigorously conducted trial with broad 
inclusion criteria and patients recruited from both primary and secondary care. The trial 
interventions were provided by NHS therapists in a real-world NHS setting. The inclusion of the cost-
effectiveness component provides further important evidence for policy makers.  
 
Conclusions 
In conclusion, the complete case analysis suggests that both the therapies are cost-effective from a 
healthcare perspective. This is reduced when using imputation methods, but the web-based CBT 
intervention remained cost-effective. Both interventions produce important savings in terms of carer 
time and if this is valued then the interventions do cover their cost. These results add important 
research evidence to support recommendations in NICE Guidelines that CBT should be offered to 
people with ongoing IBS symptoms.  
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Age (yrs) Mean (SD) 43·4 (12·5) 43·8 (13·6) 42·0 (13·5) 43·1 (13·2) 
Sex Female (%) 139 (74·7) 145 (78·4) 139 (74·3) 423 (75·8) 




Mean (SD) 16·7 (12·0) 17·3 (12·3) 17·2 (11·8) 17·1 (12·0) 
Seen a GI 
Consultant for 
IBS 



















1·0 - 65·0 
185/8·6 
0·7 - 45·4 
187/6·3 
0·3 - 49·9 
557/7·4 





























60 (32.3) 60 (32.4) 58 (31.0) 178 (31.9) 
IBS Constipation No. (%) 26 (14.0) 23 (12.4) 27 (14.5) 76 (13.6) 
IBS Alternating No. (%) 93 (50.3) 98 (53.0) 96 (51.3) 287 (51.5) 
IBS Unclassified No. (%) 6 (3.2) 4 (2.2) 6 (3.2) 16 (2.9) 
Unknown No. (%) 60 (32.3) 60 (32.4) 58 (31.0) 178 (31.9) 
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Table 2. Number (%) of participants using services at baseline and each follow-up by treatment group. 

























Gastroenterologist 29 (16) 28 (15) 37 (20) 6 (4) 5 (4) 12 (9) 4 (3) 2 (2) 10 (8) 7 (5) 8 (7) 15 (12) 
GP 149 (80) 160 (86) 162 (87) 71 (50) 67 (51) 69 (51) 71 (53) 52 (45) 68 (53) 82 (63) 71 (59) 73 (56) 
Other doctor 37 (20) 38 (21) 51 (27) 18 (13) 20 (15) 21 (16) 19 (14) 16 (14) 20 (16) 42 (32) 27 (23) 28 (22) 
Pharmacist 53 (28) 60 (32) 67 (36) 41 (29) 37 (28) 32 (24) 35 (26) 25 (22) 32 (25) 44 (34) 34 (28) 32 (25) 
Physiotherapist 18 (10) 19 (10) 24 (13) 14 (10) 9 (7) 15 (11) 19 (14) 8 (7) 14 (11) 16 (12) 12 (10) 12 (9) 
Practice nurse 67 (36) 61 (33) 80 (43) 23 (16) 27 (20) 29 (22) 23 (17) 27 (23) 27 (21) 27 (21) 26 (22) 25 (19) 
Home nurse 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 2 (2) 
Hospital nurse 11 (6) 14 (8) 21 (11) 3 (2) 14 (11) 6 (4) 6 (4) 5 (4) 7 (5) 13 (10) 11 (9) 11 (8) 
Psychiatrist 5 (3) 6 (3) 0 (0) 2 (1) 0 (0) 1 (1) 0 (0) 1 (1) 2 (2) 2 (2) 1 (1) 0 (0) 
Social worker 4 (2) 2 (1) 2 (1) 1 (1) 2 (2) 1 (1) 2 (1) 2 (2) 1 (1) 3 (2) 1 (1) 1 (1) 
Other therapist 15 (8) 21 (11) 16 (9) 7 (5) 11 (8) 7 (5) 5 (4) 9 (8) 6 (5) 7 (5) 7 (6) 6 (5) 
Acupuncturist 10 (6) 5 (3) 11 (6) 6 (4) 1 (1) 3 (2) 5 (4) 2 (2) 4 (3) 8 (6) 1 (1) 6 (5) 
Dietician 27 (15) 23 (12) 29 (16) 4 (3) 3 (2) 7 (5) 0 (0) 3 (3) 9 (7) 2 (2) 6 (5) 5 (4) 
Homeopath 8 (4) 5 (3) 4 (2) 3 (2) 0 (0) 3 (2) 3 (2) 0 (0) 0 (0) 4 (3) 2 (2) 2 (2) 
OT 3 (2) 3 (2) 1 (1) 1 (1) 1 (1) 1 (1) 3 (2) 0 (0) 0 (0) 0 (0) 2 (2) 1 (1) 
Osteopath 12 (6) 15 (8) 12 (6) 7 (5) 6 (5) 8 (6) 9 (7) 8 (7) 7 (5) 7 (5) 5 (4) 8 (6) 
Inpatient 13 (7) 11 (6) 18 (10) 3 (2) 2 (2) 2 (1) 3 (2) 1 (1) 3 (2) 8 (6) 5 (4) 7 (5) 
A & E 24 (13) 19 (10) 27 (14) 7 (5) 8 (6) 9 (7) 8 (6) 9 (8) 7 (5) 14 (11) 7 (6) 15 (12) 
Medication 99 (53) 109 (59) 108 (58) 50 (35) 56 (42) 64 (48) 45 (33) 39 (34) 58 (45) 48 (37) 46 (38) 60 (46) 
Investigations 147 (79) 138 (75) 151 (81) 45 (32) 42 (32) 42 (31) 44 (33) 24 (21) 35 (27) 62 (48) 42 (35) 51 (39) 
             
Informal care 36 (19) 36 (19) 37 (20) 21 (15) 20 (15) 26 (19) 24 (18) 19 (17) 21 (16) 13 (10) 15 (13) 22 (17) 
Lost work days 96 (52) 74 (40) 91 (49) 33 (23) 36 (27) 45 (34) 39 (29) 42 (37) 47 (37) 48 (37) 52 (43) 61 (47) 
             
 




Table 3. Mean number of service contacts among participants with at least one contact at baseline and each follow-up by treatment group. 

























Gastroenterologist 1·5 2·8 2·6 1·2 1·4 1·2 2·3 11·0 1·3 1·3 1·6 3·7 
GP 3·9 3·8 4·2 2·4 2·1 3·0 2·0 2·3 2·7 2·0 2·4 2·6 
Other doctor 3·6 2·1 3·4 2·3 1·8 1·8 4·7 2·1 1·5 1·6 2·1 2·6 
Pharmacist 3·6 4·4 4·4 3·0 2·7 2·8 2·0 2·2 2·0 2·0 2·1 2·6 
Physiotherapist 3·2 6·5 6·0 3·4 3·0 1·9 3·6 2·9 3·7 3·9 4·3 3·2 
Practice nurse 2·1 2·2 1·7 1·7 1·6 1·3 1·9 1·3 1·5 1·6 1·5 1·6 
Home nurse 2·0 - - - - - - - - 20·0 - 2·0 
Hospital nurse 2·7 2·0 1·4 1·7 1·7 1·2 2·2 1·6 1·3 1·8 1·4 1·8 
Psychiatrist 3·0 2·0 - 2·5 - 1·0 - 3·0 2·0 2·5 2·0 - 
Social worker 3·5 6·0 1·0 3·0 6·0 1·0 3·0 1·0 1·0 2·3 1·0 4·0 
Other therapist 5·7 7·3 5·9 5·6 3·8 3·9 4·4 4·8 2·0 2·9 5·0 2·7 
Acupuncturist 4·4 4·8 5·4 1·8 5·0 2·0 3·6 2·0 1·5 4·1 1·0 3·3 
Dietician 1·7 1·6 1·8 1·0 3·0 1·4 - 1·0 1·7 1·0 2·2 1·4 
Homeopath 2·5 2·4 11·0 3·3 - 1·0 1·7 - - 1·0 1·0 2·5 
OT 4·3 3·3 1·0 6·0 3·0 1·0 1·7 - - - 4·0 1·0 
Osteopath 3·1 4·0 3·3 1·7 2·3 2·4 2·3 1·3 1·7 1·9 5·2 2·1 
Inpatient - - - - - - - - - - - - 
A & E 1·3 1·2 1·3 1·0 1·1 1·6 1·0 1·3 1·0 1·1 1·0 1·3 
Medication - - - - - - - - - - - - 
Investigations 2·6 2·7 2·6 1·8 2·5 2·0 1·9 1·6 1·9 3·1 2·0 2·0 
             
Informal care 9·6 11·5 12·9 6·7 7·5 10·7 7·2 4·8 26·0 5·6 10·0 16·5 
Lost work days 10·3 10·2 9·8 8·5 5·1 5·3 9·9 3·1 6·9 7·9 4·3 11·5 
             
 




Table 4. Mean cost of service contacts at baseline and each follow-up by treatment group (2015/16 £s). 

























Gastroenterologist 32 57 69 7 7 14 9 26 14 9 15 59 
GP 106 110 122 39 36 50 34 35 47 42 47 48 
Other doctor 97 57 124 39 36 37 90 39 32 70 65 77 
Pharmacist 26 36 40 22 19 17 13 12 13 17 15 16 
Physiotherapist 15 33 38 16 10 11 25 10 20 24 21 14 
Practice nurse 11 11 11 4 5 4 5 5 5 5 5 5 
Home nurse <1 0 0 0 0 0 0 0 0 4 0 1 
Hospital nurse 7 7 7 2 8 2 4 3 3 8 5 7 
Psychiatrist 11 9 0 5 0 1 0 4 4 5 2 0 
Social worker 3 3 <1 1 4 <1 2 1 <1 2 <1 1 
Other therapist 36 66 40 22 25 16 13 30 7 12 23 10 
Acupuncturist 12 6 16 4 2 2 7 2 2 13 <1 8 
Dietician 20 16 22 2 6 6 0 2 9 1 9 4 
Homeopath 5 3 12 4 0 1 2 0 0 2 1 2 
OT 6 4 <1 3 2 1 3 0 0 0 5 1 
Osteopath 10 16 10 4 5 7 8 4 5 5 11 7 
Inpatient 163 71 156 56 121 13 24 17 17 202 36 103 
A & E 23 16 27 7 9 14 8 14 8 17 8 20 
Medication 23 28 36 6 12 15 5 6 12 11 15 20 
Investigations 98 99 108 35 52 32 36 22 21 81 55 43 
Total health cost 681 620 802 271 346 227 280 224 206 519 325 393 
             
Informal care 759 915 1048 203 232 423 261 161 873 230 510 1144 
Lost work days 556 430 502 208 145 186 299 118 265 307 195 566 
Total cost 1995 1965 2352 682 723 836 840 503 1344 1055 1029 2103 
 





Table 5. EQ-5D-5L utility scores by time period and quality-adjusted life years (QALYs). 
 TCBT (n=186) WCBT (n=185) TAU (n=187) 
 N (%) Mean (sd) N (%) Mean (sd) N (%) Mean (sd) 
Baseline 185 (99) 0·8191 (0·1283) 185 (100) 0·8016 (0·1651) 187 (100) 0·8101 (0·1468) 
0-3 month follow-up 147 (79) 0·8499 (0·1253) 133 (72) 0·8392 (0·1657) 132 (71) 0·8083 (0·1547) 
3-6 month follow-up 134 (72) 0·8761 (0·1128) 112 (60) 0·8563 (0·1404) 128 (68) 0·8251 (0·1438) 
6-12 month follow-up 120 (65) 0·8799 (0·1425) 113 (61) 0·8459 (0·1513) 123 (66) 0·8265 (0·1497) 




Table 6. Sensitivity analyses based on different therapy costs. 
 Incremental costs and ICERs (£s) following reductions/increases in therapy costs 











614 785 956 1126 1297 
ICER 14,312 18,298 22,284 26,247 30,233 




97 160 224 288 352 
















































































































Figure captions (see separate files) 
 
Figure 1. Cost-effectiveness plane for TCBT v TAU (healthcare perspective, complete case analysis). 
 
Figure 2. Cost-effectiveness plane for WCBT v TAU (healthcare perspective, complete case 
analysis). 
 
Figure 3. Cost-effectiveness acceptability curves based on QALYs. 
 
 
